Top Section/Ad
Top Section/Ad
Most recent
Naturgy and Zurich fall in secondary market after jumbo blocks
Capital raise and investor selldown follow €3bn raise by Engie on Friday evening
UKPN purchase seen as positive by rating agencies, leads to senior and hybrid upgrades
More articles/Ad
More articles/Ad
More articles
-
Fintech was one of the hottest sectors in equity capital markets in 2019 and it seems to have lost none on its appeal during the coronavirus pandemic, as two deals on Tuesday demonstrated. -
Equity capital markets have been relentless since the first coronavirus rescue issues in the spring. There is no let-up, with several large deals announced in the past fortnight and scheduled to be priced in August. However, bankers are worried that tired investors are near breaking point.
-
EMEA’s equity capital markets were buzzing on Friday morning after Goldman Sachs placed a 13.2m block of shares in Cellnex, the Spanish telecoms tower company, which allowed the company’s largest shareholder to monetise rights that it intends not to exercise in the issuer's forthcoming €4bn rights issue.
-
Sino Biopharmaceutical’s chief executive Tse Ping has sold a portion of his stake in the company for the second time this year, pocketing HK$3.15bn ($406.4m) but causing the stock price to tumble in the secondary market.
-
BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.
-
Asian Development Bank offloaded chunks of Thai energy companies B.Grimm Power and Gulf Energy Development this week, raising Bt9.6bn ($303.9m).
